A ROBOT WANTS TO MIX YOUR CLIENT'S HOMECARE, AND IT IS OFFERING TO PUT YOUR NAME ON THE LABEL TOO
SmartSKN will sell you a skin scanner, compound every order in a lab you will never visit, and pay you a commission on a client who is now, in every practical sense, theirs.
Almost every conversation I have about retail comes back to the same tension, and it looks different depending on the size of the business. In a salon with a stockroom, there is money sitting on those shelves, usually a good deal more than the owner is comfortable saying out loud, and some of it will be written off because it was ordered to hit a wholesale target rather than because a client asked for it. In a rented room, salon suite or home business, the problem is the opposite, because the opening order for a decent cosmeceutical brand is more cash than the business can spare and the minimum monthly spend is more than a single therapist column can absorb. Both of those owners have a retail problem, and a brand that arrives offering retail with no stock, no capital outlay, no minimum order, and no expiry risk is speaking to both of them at once.
If salon owners reading this feel that tension, let me introduce you to SmartSKN. It is running a provider network in the United States where a licensed skin professional buys a diagnostic device, scans a client, and the resulting formula is compounded to order by a robotic lab and shipped directly to that client's door, with the salon paid a commission on the sale. The salon never stocks a product on their shelves.
What SmartSKN actually is
SmartSKN is an American company built on Korean technology. It paid $7 million to LillyCover for the exclusive right to bring LillyCover's AI-driven on-demand skincare production robots into the US market, and the robots themselves are manufactured by Lillycover in Korea, which also supplies the licensed technology and the ingredients behind the formulations. Lillycover was founded in Seoul in 2016 by SunHee An, who came to skincare from computer engineering and from developing medical devices for burn patients, and the business has been through Beiersdorf's NIVEA accelerator program and raised a Series A led by POSCO Capital. This is not another quickly set up AI skincare company, and the underlying science has had close to a decade of development behind it.
The professional arm is called K-PRO, and it sits alongside a consumer line and a build-your-own platform. Formulations are delivered fresh and on demand, with the pitch to professionals being no inventory and no upfront product cost.
The technology behind it
The diagnostic end is a device called the Muilli AI Dermascope. It uses a 60x magnification camera to capture five areas of the face (cheeks, forehead, eye area, nose, and chin) along with a microcurrent moisture sensor placed on both cheeks to read moisture and oil, after which the client completes a skin questionnaire that feeds the algorithm. The published specification covers hydration, oil balance, pore size, redness, sensitivity, pigmentation, wrinkles, dryness, and blemishes, with the model trained on more than 150,000 skin profiles.
At the manufacturing end, the robot builds a base product and adds two active complexes chosen for the skin's immediate needs as the analysis reads them, and SmartSKN puts the number of possible formulations at more than 25,000.
How it works inside a salon
It's pretty simple actually. You scan the client and review the biomarkers with her, the platform generates her formula, and she is sent a link to check out and pay. The client has thirty days to complete the purchase, the robot makes the products once she does, and the order is drop-shipped straight to her, with the therapist paid a commission on the sale. Further orders continue to earn commission between appointments for as long as the order remains attributed to the salon.
But wait, there's more. Approved providers can apply to have their salon name printed on the personalised label, with approval granted on activity, client engagement, brand fit, and growth potential, which is a polite way of saying it is awarded at the brand's discretion rather than earned by contract.
What it costs, and what it takes to earn it back
The Muilli device is a one-time purchase of $999 and is compulsory for joining the provider network. That price includes a twelve-month warranty, one-on-one onboarding, platform training, provider certification, unlimited scans, access to their Provider Academy, the provider portal, directory visibility, and marketing resources, with no subscription and no per-scan fee. There are no minimum orders and no stock to buy.
Commission is quoted at 30% to 50% on eligible orders, with the rate set by monthly tier rules and the base rate being the one worth planning against. Their illustrative scenario assumes 30 active formula clients, six eligible orders per client per year, an average order of $255, and commission at the base 30% rate, excluding any revenue you charge for the scan itself.
Play that out and it is $45,900 in client spend, returning $13,770 a year to the salon at 30%, or $22,950 if you reached the top of the commission band. Against a $999 device, break-even arrives at fourteen orders at the base rate, or eight at the top rate, so the hardware pays for itself inside the first two or three committed clients.
Six orders a year means a client rebuying every eight weeks or so, every eight weeks, for a full year, without lapsing. If half your thirty clients hold that pattern and the rest buy twice, you are closer to $7,000 than $14,000, which is still real money for something that occupies no shelf space at all.
In AUD for us on the big island, that means the device lands near $1,500 and the average order near $390, and the platform is licensed for the United States only, so none of this is buyable here today. On a three-product routine at 30ml each, $390 works out around $4.35 a millilitre, which sits comfortably inside what an Australian client already pays for a cosmeceutical serum. The ask is not the unit price, it is persuading her to buy the whole routine in one transaction with nothing in her hand to take home.
Who this actually suits, and why the reasons are opposite
Two very different businesses will look at this model and see something worth having, and almost nothing in their reasoning overlaps.
For a solo operator, a chair renter, or anyone running from a single room, the appeal is that it removes the barrier that has kept her out of professional retail altogether. Most cosmeceutical brands ask for an opening order she cannot justify against her client volume, set a minimum monthly spend she cannot reliably hit, and in plenty of cases will not open an account for a business her size at all. Where she does get an account, the stock turns slowly enough that she is watching batch dates rather than counting margin, and the storage is a cupboard that also holds her linen. Against that, thirty per cent of a sale she could never otherwise have made comfortably beats fifty per cent of a sale she was never going to make, and her name printed on the label is worth disproportionately more to someone who does not yet have a brand of her own. This matters more here than it might elsewhere, because the Australian industry is moving further toward solo operating rather than away from it, with 46.5% of Australian hairdressers now self-employed (ABS 2021 Census, via SaCSA) and ATO-recorded chair rental arrangements having climbed from around 2,200 to 6,600 inside a single year.
For a multi-room salon or a clinic with a team, inventory was never the pain, so the case has to be made somewhere else. What the model offers there is consistency, because a scanner and an algorithm give a room full of therapists with very different levels of experience the same consultation to deliver, and the scan itself becomes a chargeable service that fills a gap in the treatment menu rather than sitting inside an existing appointment for free. The volume argument is also completely different, since thirty active formula clients is a rounding error for a clinic with several hundred on the books, and the same model run across a real database produces numbers that are worth a board conversation.
The catch for the larger business is one the solo operator does not have. Commission at thirty per cent arrives in place of a wholesale margin you were already earning at closer to fifty, so every client who moves across takes a cut in per-dollar terms, and you are trading that against a brand relationship that currently supplies your training, your BDM, your co-op marketing, and your launch support. There is an operational wrinkle underneath it too, because your retail commission structure almost certainly pays therapists on sales invoiced through your point of sale, and this revenue arrives outside the POS, from a third party, on a monthly cycle. Somebody has to decide what the therapist who performed the scan is owed, and that decision is easier to make before the first payment lands than after.
The honest read is that this model solves a cash and access problem elegantly and solves a margin problem poorly, so the question worth sitting with is which of those two problems you actually have.
Where it helps and where it hurts
What it touches | The case for | The catch |
Working capital | No stock purchase and no expiry write-offs, which matters most to the operator who has never been able to afford an opening order in the first place | Your return on capital is excellent because there is no capital, which is a different thing from earning more dollars |
Margin | 30% to 50% on every order with nothing bought, shipped, or stored | A wholesale account at 50% off RRP pays you more per dollar sold, and the top commission tier is awarded rather than contracted |
The consultation | The scan is a chargeable service and a legitimate reason to book a skin appointment that is not a treatment | It relocates diagnostic authority from your therapist to a device, and clients notice who is actually deciding |
Reorders | Commission accrues between visits without a retail conversation or a follow-up call | Nothing brings her back through your door to get it, so the reorder and the rebooking stop being the same event |
Post-treatment aftercare | The end-of-treatment conversation becomes a scan and a link rather than a pitch | Nothing goes home with her that night, so time-critical aftercare arrives days late and your result wears the consequence |
The client relationship | Her name, her formula, her history, and her reorder dates are all captured against your salon | The platform holds the customer, the payment, the data, and the attribution rule that decides whether you are still paid |
Branding | Your salon name on a bottle on her bathroom shelf, which no third-party brand will ever give you | Co-branding is granted on brand fit and growth potential, and anything granted can be withdrawn |
Paying your team | Retail revenue keeps arriving without anyone needing to close a sale on the floor | It lands outside your POS on someone else's cycle, so your existing therapist commission structure does not know what to do with it |
Risk | No obsolete stock, no discounting old lines, and no freight on things nobody wanted | Compounded-to-order skincare has a long history of launching loudly and not scaling, and your client data sits inside someone else's platform |
Availability | Proven technology with real Korean R&D and institutional backing behind it | US-only today, compounded and shipped from the US, with the freight and compliance questions that follow |
The question underneath all of it
Every part of this is defensible except one, and it is the part the commission rate distracts from. When the formula, the checkout, the payment, the packaging, the shipping, and the reorder prompt all belong to the platform, what you own is a referral, tracked by a rule that the brand can rewrite. Their own language gives it away in the phrase about the order remaining attributed to the salon. Attribution is something you are given.
Compare that against the account you already have with a brand you stock. The margin is better, the stock is a nuisance, and the client walks out with the product in her hand because you put it there.
The walking-out part matters more clinically than it sounds, because homecare prescribed after a peel or after needling is time-critical in a way that maintenance retail never is, and the barrier support and the SPF are needed that night rather than the following week. A formula compounded to order and shipped from an overseas lab will take days at best, and longer once customs has had a look at it, and with a thirty-day checkout window sitting in front of all that, the order might not even be placed for a fortnight. In the meantime she reaches for whatever is already in her bathroom cabinet, which is very often the product you have just spent an hour correcting for, and when her result comes in softer than the one you promised her, she is not going to put that down to a freight schedule, she is going to put it down to you.
The same delay costs you commercially, because her intent starts decaying the moment she leaves the room. The most persuasive minute in the whole relationship is the one where she is still in your chair looking at her own skin in your mirror while you talk her through what you can see, so asking her to complete that purchase later, on her own phone, is asking her to reconvince herself without you there.
None of this makes the model useless, though it does tell you where it fits. A repeat order of a serum she already knows and likes is in no hurry at all, so replenishment can sit with a robot in another country quite happily, while aftercare attached to a treatment cannot, which points toward running something like this alongside a small core of stocked aftercare rather than in place of one, and being honest with yourself about which of your retail dollars are truly which.
If you could buy this in Australia tomorrow
You cannot yet, but the technology is being licensed market by market, and Lillycover is actively signing partners to deliver personalised products to local customers in each market, so a version of this reaching us is a matter of when.
There are four short questions I would want answered before that. What happens to my attribution if she books elsewhere, who owns her scan data and her formula history, what moves a salon between commission tiers and what moves it back down, and what are the grounds for withdrawing co-branding. Any brand confident in its offer will answer all four without flinching.
Comments